4.7 Review

Muscular dystrophy in a dish: engineered human skeletal muscle mimetics for disease modeling and drug discovery

Journal

DRUG DISCOVERY TODAY
Volume 21, Issue 9, Pages 1387-1398

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2016.04.013

Keywords

-

Funding

  1. Muscular Dystrophy Association (MDA) [255907, 381465]
  2. National Institutes of Health [R21AR064395]
  3. New York Stem Cell Foundation
  4. International Collaborative RD Program
  5. KIAT - MOTIE [N0000894]
  6. Department of Bioengineering at the University of Washington
  7. Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea [N0000894] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Engineered in vitro models using human cells, particularly patient derived induced pluripotent stem cells (iPSCs), offer a potential solution to issues associated with the use of animals for studying disease pathology and drug efficacy. Given the prevalence of muscle diseases in human populations, an engineered tissue model of human skeletal muscle could provide a biologically accurate platform to study basic muscle physiology, disease progression, and drug efficacy and/or toxicity. Such platforms could be used as phenotypic drug screens to identify compounds capable of alleviating or reversing congenital myopathies, such as Duchene muscular dystrophy (DMD). Here, we review current skeletal muscle modeling technologies with a specific focus on efforts to generate biomimetic systems for investigating the pathophysiology of dystrophic muscle.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available